Poor
Poorly Aligned
Patient Risk:
Low
Summary
Most extracted claims are not supported by the FDA-approved Lipitor label; only a single claim about obtaining lipid/CK monitoring is supported. Several statements assert interactions or recommendations not present in the label.
Category Scores
Accurate Statements
Get bloodwork to check lipids and CK levels.
17, 5.1
Unsupported Statements
Lipitor (atorvastatin) and omega-3 supplements, such as fish oil, can generally be combined safely.
Not described in label; no explicit guidance on omega-3 co-administration safety.
Clinical data shows no significant pharmacokinetic interactions between statins like atorvastatin and omega-3 fatty acids (e.g., EPA/DHA).
No omega-3 interaction data is provided in the label; PK interactions table covers other co-medications, not omega-3s.
A 2014 meta-analysis in the Journal of Clinical Lipidology found that adding omega-3s to statin therapy enhances triglyceride reduction.
Not described in the label.
A 2014 meta-analysis in the Journal of Clinical Lipidology found that adding omega-3s to statin therapy does not increase adverse events.
Not described in the label.
No major drug-supplement interactions are reported in databases like Drugs.com or the Natural Medicines Database.
Not described in the label.
Omega-3s do not alter atorvastatin's metabolism via CYP3A4 pathways, unlike grapefruit juice.
Not described in the label.
A 2020 Circulation review confirmed co-administration lowers cardiovascular risk in high-triglyceride patients.
Not described in the label.
A 2020 Circulation review confirmed co-administration does not elevate myopathy or rhabdomyolysis rates.
Not described in the label.
Real-world use in REDUCE-IT trial participants (on statins plus icosapent ethyl, a purified omega-3) showed safety.
Not described in the label.
Both can cause mild gastrointestinal upset.
Not described in the label.
Bleeding risk at high doses (omega-3 >3 g/day).
Not described in the label.
Statins alone carry muscle pain risk (5-10% of users).
Not described in the label; the label provides qualitative myopathy/rhabdomyolysis information, not a percentage.
Omega-3s do not amplify this.
Not described in the label.
Monitor liver enzymes if on high-dose omega-3s (>4 g/day).
Not described in the label.
Rare transaminase elevations occur independently.
Not described in the label.
No evidence of increased LDL cholesterol.
Not described; label indicates LDL-C reductions with statins.
For standard Lipitor dose (10-80 mg daily) pairs with 1-4 g omega-3s (EPA/DHA combined).
Not described in the label.
For triglycerides >500 mg/dL, prescription omega-3s like Vascepa (2-4 g) are preferred over OTC supplements for purity.
Not described in the label.
Take omega-3s with meals to reduce fishy aftertaste.
Not described in the label.
Space from Lipitor if stomach issues arise.
Not described in the label.
Vascepa (icosapent ethyl) is a common add-on.
Not described in the label.
Its key patent expires in 2030, with generic entry possible sooner via settlements.
Not described in the label.
Lovaza (GSK) patent expired in 2014, allowing generics.
Not described in the label.
Consult a doctor before starting, especially with bleeding disorders, planned surgery, or other meds like blood thinners.
Not described in the label.
Choose third-party tested supplements (USP/NSF) to avoid contaminants like mercury.
Not described in the label.
Contradictions
Important Omissions
The claims heavily discuss omega-3 interactions and dosing, which are not addressed in the Lipitor label beyond general lipid management and co-medication interactions. There is no explicit guidance on omega-3–atorvastatin combinations, dosing for triglyceride management, or OTC vs prescription omega-3 considerations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label supports monitoring for statin-associated myopathy and hepatic effects, but many AVI claims about omega-3 interactions are not described; no new safety signals identified from the provided label data.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Most extracted claims are not supported by the FDA-approved Lipitor label and may mislead regarding omega-3 interactions and co-administration.
Suggested Improvement
Restrict statements to information explicitly present in the label (e.g., CK and liver monitoring, known drug interactions). Remove or clearly contextualize claims about omega-3 interactions, dosing synergies, and OTC vs prescription omega-3 products unless supported by labeling.